Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| BPC-157 | GHK (without copper) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection near the site of injury. | Research indicates 1-3% concentration in topical formulations. Injectable dosing follows GHK-Cu protocols at 1-2 mg daily. |
| Timing | Administer on an empty stomach or near the injury site. No strict meal timing required, though fasted state may improve absorption for oral dosing. | Topical application morning and evening. Injectable in evening. |
| Cycle Duration | Typical cycles range from 4-12 weeks depending on the injury being addressed. | Topical use can be ongoing indefinitely. Injectable cycles 8-12 weeks. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
BPC-157 is a 15-amino acid peptide derived from human gastric juice that promotes angiogenesis via dual VEGFR2-dependent (PI3K-Akt-eNOS) and VEGF-independent (Src-Caveolin-1-eNOS) nitric oxide pathways. It upregulates growth hormone receptor expression, modulates the FAK-paxillin pathway for cell migration, and counteracts damage to the nitric oxide system. Additionally, it enhances tendon fibroblast growth, promotes reticulin and collagen formation, and accelerates wound healing by mediating the NO system's protective functions.
Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection near the site of injury.
Administer on an empty stomach or near the injury site. No strict meal timing required, though fasted state may improve absorption for oral dosing.
Typical cycles range from 4-12 weeks depending on the injury being addressed.
GHK (glycyl-L-histidyl-L-lysine) is a naturally occurring tripeptide found in human plasma, saliva, and urine that has an extremely high affinity for copper(II) ions. Even without exogenously complexed copper, GHK rapidly chelates available copper in biological systems, making copper-free GHK functionally similar to GHK-Cu in vivo. The peptide stimulates collagen and glycosaminoglycan synthesis, modulates metalloproteinase activity, resets gene expression patterns toward a healthier state (affecting 31.2% of human genes), and activates wound healing cascades.
Research indicates 1-3% concentration in topical formulations. Injectable dosing follows GHK-Cu protocols at 1-2 mg daily.
Topical application morning and evening. Injectable in evening.
Topical use can be ongoing indefinitely. Injectable cycles 8-12 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →